Celyad Oncology SA (EBR:CYAD)

Celyad Oncology Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	0.02	0.19	0.1	-	-
Revenue Growth (YoY)	-88.71%	82.35%	-	-	-
Cost of Revenue	0.01	0.01	0.07	-	-
Gross Profit	0.01	0.17	0.03	-	-
Selling, General & Admin	3.78	3.2	6.25	10.56	10
Research & Development	3.42	3.24	4.38	18.91	20.69
Other Operating Expenses	-8.06	-0.39	-1.05	-4.03	-3.44
Operating Expenses	-0.87	6.04	9.58	25.45	27.24
Operating Income	0.88	-5.87	-9.54	-25.45	-27.24
Interest Expense	-0.06	-0.12	-0.08	-0.2	-0.26
Interest & Investment Income	-	0.15	0.03	0.01	0.03
Currency Exchange Gain (Loss)	-	-	-	0.17	0.01
Other Non Operating Income (Expenses)	0.01	-	-	-0	0.11
EBT Excluding Unusual Items	0.83	-5.84	-9.6	-25.46	-27.35
Impairment of Goodwill	-	-	-	-0.64	-
Gain (Loss) on Sale of Assets	-	0.01	1.09	5	-0
Asset Writedown	-	-	-	-34.44	-
Other Unusual Items	-	-	-	14.68	0.85
Pretax Income	0.83	-5.82	-8.51	-40.87	-26.5
Income Tax Expense	-	-	-0.06	0.07	0.01
Net Income	0.83	-5.82	-8.45	-40.94	-26.51
Net Income to Common	0.83	-5.82	-8.45	-40.94	-26.51
Shares Outstanding (Basic)	46	41	26	23	16
Shares Outstanding (Diluted)	46	41	26	23	16
Shares Change (YoY)	11.30%	61.06%	13.84%	44.80%	11.92%
EPS (Basic)	0.02	-0.14	-0.33	-1.81	-1.70
EPS (Diluted)	0.02	-0.14	-0.33	-1.81	-1.70
Free Cash Flow	-6.9	-5.68	-16.1	-28.13	-26.97
Free Cash Flow Per Share	-0.15	-0.14	-0.63	-1.25	-1.73
Gross Margin	61.91%	93.55%	32.35%	-	-
Operating Margin	4195.24%	-3155.91%	-9356.86%	-	-
Profit Margin	3952.38%	-3131.18%	-8282.35%	-	-
Free Cash Flow Margin	-32857.14%	-3053.76%	-15785.29%	-	-
EBITDA	1.06	-5.69	-9.04	-24.74	-26.68
EBITDA Margin	5066.67%	-	-	-	-
D&A For EBITDA	0.18	0.18	0.51	0.71	0.56
EBIT	0.88	-5.87	-9.54	-25.45	-27.24
EBIT Margin	4195.24%	-	-	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.